We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Cyto-reduction of neuroendocrine tumours using Sandostatin LAR® in combination with Infergen®: results of a case series.
- Authors
Wang, Hank S.; Oh, David S.; Ohning, Gordon V.; Pisegna, Joseph R.
- Abstract
Historically, limited trials evaluating biotherapy in treating metastatic neuroendocrine tumours have yielded mixed results. In this study, the efficacy of a novel combination therapy featuring long-acting Sandostatin LAR® plus α-interferon was evaluated. In a prospective case series, 12 patients with unresectable metastatic neuroendocrine tumours refractory to treatment initiated therapy with Infergen® and Sandostatin LAR®. Radiological response was followed serially at 3-month intervals. A biochemical response was considered significant if marker levels decreased by ≥50% compared with baseline. Inhibition of tumour growth lasting for greater than 3 months (mean response 22.6 ± 17.7 months) was seen in eight patients. Complete tumour regression was observed in one patient, lasting for 40 months; three patients exhibited partial tumour regression (mean response 29.3 ± 24.0 months), and four patients maintained a stable tumour response (mean response 13.3 ± 9.2 months). Four patients showed no response to therapy (mean response 5.0 ± 6.0 months). All enrolled patients are alive currently. The biochemical response seen in seven patients did not correlate with the radiological response. These results suggest that the novel combination of long-acting Sandostatin LAR® with an α-interferon may be at least as effective as either combination therapy with short-acting octreotide or monotherapy with Sandostatin LAR®.
- Publication
Journal of Pharmacy & Pharmacology, 2006, Vol 58, Issue 12, p1623
- ISSN
0022-3573
- Publication type
Article
- DOI
10.1211/jpp.58.12.0009